In clinical settings, researchers sequenced the somatic genomic mutations of three HR+ breast cancer samples before and after drug resistance to CDK4/6 inhibitors occurred and found that Rb1 mutation, allele substitution or exon deletion only existed in the blood samples after but not before drug resistance (20). Here, CDK4 is linked to breast cancer.